NYXH — Nyxoah SA

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1857190 · Belgium
Last close
$1.71
Market Cap
$171.12M
52W High
$3.42
52W Low
$1.26
ADV30
555,666
Next earnings
2026-08-05
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 6,372,000 3,638,000 -20,503,000 -15,944,000 97,598,000 12,934,000 61,727,000
Dec 2025 5,644,000 3,625,000 -18,259,000 -23,513,000 118,471,000 30,001,000 69,342,000
Sep 2025 1,972,000 1,193,000 -24,195,000 -23,580,000 93,599,000 10,869,000 42,645,000
Jun 2025 1,340,000 850,000 -19,850,000 -20,607,000 116,470,000 22,729,000 43,073,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-59,359,000
Investing CF
$785,000
Financing CF
$71,767,000
CapEx
$-3,783,000
Dividends Paid
$0
Buybacks
EPS Diluted TTM
$-2.37
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-306,029,000
Inventory
$4,660,000
Receivables
$7,578,000
ST Investments
$18,000,000
EBIT TTM
$-87,385,000
Pretax Income TTM
$-89,076,000
Interest Exp TTM
$1,691,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$15,328,000
EBITDA
$-82,043,000
Free Cash Flow
$-45,774,752
Enterprise Value
$83,062,216
Total Cash
$25,934,000
Total Debt
$36,080,000
Shares Out
100,072,815
Trailing EPS
$-2.43
Book Value
$0.94
ROE
-130.0%
ROA
-44.6%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 10,020,000 -82,942,000 -90,085,000 118,471,000 69,342,000 -68,979,000
Dec 2024 4,521,000 -58,809,000 -59,236,000 158,406,000 45,152,000 -49,226,000
Dec 2023 4,348,000 -45,102,000 -43,212,000 124,157,000 26,135,000 -44,778,000
Dec 2022 3,084,000 -32,499,000 -31,225,000 146,071,000 25,747,000 -28,756,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.21

Peers — same industry

TickerNameMarket CapLastDaily %
STXS Stereotaxis, Inc. $166.15M $1.70
INGN Inogen Inc $177.07M $6.54
APYX Apyx Medical Corp $184.44M $4.38
LUCD Lucid Diagnostics Inc. $190.77M $1.00
EMBC Embecta Corp. $192.22M $3.24

News headlines (Yahoo Finance, 1h cache)

Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day
2026-07-10 23:02 · Yahoo
Nyxoah (ENXTBR:NYXH) Stock Fair Value Moves Lower After Capital Raise And Analyst Caution
2026-07-08 09:15 · Yahoo
Nyxoah Announces Preliminary Results for the Second Quarter of 2026
2026-07-07 20:05 · Yahoo
Information on the total number of voting rights and shares
2026-06-30 20:30 · Yahoo
Publication relating to transparency notifications
2026-06-29 20:30 · Yahoo
Nyxoah (ENXTBR:NYXH) Stock Fair Value Moves Lower After Analyst Cuts And Capital Concerns
2026-06-24 04:30 · Yahoo
Nyxoah to Host Investor Day in New York on July 8, 2026
2026-06-23 20:05 · Yahoo
Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 9, 2026
2026-06-19 20:30 · Yahoo
Nyxoah Receives $15 Million from the European Investment Bank
2026-06-17 20:05 · Yahoo
Nyxoah’s Genio® Wins Prix Galien UK 2026 Award for Best Medical Technology
2026-06-15 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.